Evidence map›Paper›PMID 37814352›Full record

ArticlePilot and feasibility studies2023

A pilot randomised controlled parallel arm trial evaluating treatment satisfaction with the Omnipod DASH

Yee Wen Kong, Cheng Yi Yuan, Katerina Kiburg, Katrin Brown, Steven Trawley, Andi Partovi, Kerryn Roem, Natalie Harrison, Spiros Fourlanos, Elif I Ekinci and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pilot and feasibility studies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yee Wen KongDiabetes Technology Research Group, The University of Melbourne, Melbourne, VIC, Australia.
Cheng Yi YuanDiabetes Technology Research Group, The University of Melbourne, Melbourne, VIC, Australia.
Katerina KiburgDiabetes Technology Research Group, The University of Melbourne, Melbourne, VIC, Australia.
Katrin BrownDiabetes Technology Research Group, The University of Melbourne, Melbourne, VIC, Australia.
Steven TrawleyDiabetes Technology Research Group, The University of Melbourne, Melbourne, VIC, Australia.
Andi PartoviKeylead Health, Melbourne, VIC, Australia.
Kerryn RoemDiabetes Technology Research Group, The University of Melbourne, Melbourne, VIC, Australia.
Natalie HarrisonGeelong Endocrinology and Diabetes, Geelong, VIC, Australia.
Spiros FourlanosDepartment of Medicine, The University of Melbourne, 4th Floor, Clinical Sciences Building, 29 Regent Street, Fitzroy, VIC, Australia.
Elif I EkinciDepartment of Medicine, The University of Melbourne, 4th Floor, Clinical Sciences Building, 29 Regent Street, Fitzroy, VIC, Australia.
David N O'NealDiabetes Technology Research Group, The University of Melbourne, Melbourne, VIC, Australia. dno@unimelb.edu.au.ORCID http://orcid.org/0000-0002-0870-4032
The University of Melbourne · AUMelbourne Health · AUThe Royal Melbourne Hospital · AU

Funding

Insulet Corporation B81A2221-4FA2-4630-916B-371A3ACBD00A
6 · The paper itself

Abstract

backgroundInsulin pump therapy (IPT) improves glucose control in people with type 1 diabetes (T1D) compared with multiple daily injections (MDI). However, their size, the tethered insulin infusion set, intrusiveness when operating the device and the need to disconnect during showering limit their acceptance to many who may benefit. The Omnipod DASH

methodsA pilot multi-site parallel randomised controlled study will be conducted in sixty-four adults with T1D who are managed on MDI or IPT and self-monitoring with finger-stick blood glucose from four specialist diabetes centres in Victoria, Australia. Following carbohydrate counting education, participants will be randomised to use Omnipod DASH DISCUSSION: This pilot study will provide insights regarding the feasibility of the study design and the first data regarding user acceptance of insulin patch pump technology in Australian T1D adults. We anticipate that this study will provide information informing the design of a larger study evaluating the impact of patch pumps on subjective outcomes that are of significance to the person living with T1D.

trial registrationAustralian New Zealand Clinical Trials Registry ( https://anzctr.org.au/ ) ACTRN12621001195842 (8th September 2021). Please refer to Additional file 1: Appendix 1 for full details.

Indexed as

Insulin pump therapyPatch pumpTreatment satisfactionType 1 diabetes

Identifiers

PMID37814352
PMCPMC10561483
OpenAlexW4387456293

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.